ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
The m6 A modification of CDKN2 A inhibites ferroptosis and affects the resistance of cervical squamous cell carcinoma to cisplatin.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- RNA modifications and cancer ferroptosis.Cancer cell international · 2026Review
- Discovery of a Ferroptosis-Related lncRNA-miRNA-mRNA Gene Signature in Endometrial Cancer Through a Comprehensive Co-Expression Network Analysis.Current oncology (Toronto, Ont.) · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cervical squamous cell carcinoma (CESC) is the fourth most common malignancy and the fourth leading cause of cancer deaths in women worldwide. Despite advances in treatment, cisplatin-based radiotherapy remains the primary treatment option. However, cisplatin resistance is a major challenge, leading to poor prognosis. Therefore, understanding the molecular mechanisms underlying cisplatin resistance is crucial for developing novel therapeutic strategies. Through bioinformatics analysis, we investigated the expression of CDKN2A in the CESC database. WB, IHC, qPCR, and CCK-8 were used for clinical analysis of CDKN2A expression and its correlation with CESC cell proliferation. Through qPCR, CCK-8, ROS, MDA, Fe
Indexed as
Identifiers
40372475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.